Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 23, 2004. The report details corporate actions regarding share buybacks and changes in directors' interests in ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 19, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on specific share transaction data:
- Share Buyback (Cancellation): 2,275,000 ordinary shares purchased at 1,098.3524p per share on February 18, 2004.
- Share Buyback (Treasury): 1,870,000 ordinary shares purchased at 1,065.12p per share on March 22, 2004.
- Treasury Holdings: Following the March 22 transaction, the company holds 1,870,000 shares in treasury.
- Shares in Issue: 5,936,333,745 shares (excluding treasury shares).
- Employee Plan Purchases: 338,386 shares purchased on behalf of participants in the Annual Investment Plan at £10.66 per share.
Material Changes
The filing reports specific reductions in the company's share capital through cancellation and the accumulation of treasury stock. There are no reported material changes to the company's core business operations, revenue streams, or financial position compared to prior periods within this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural disclosure of share transactions and director interest changes.
Key Facts for Investor Verification
- Verify the total number of shares held in treasury (1,870,000) against subsequent filings to confirm no further buybacks or releases occurred.
- Confirm the total issued share count of 5,936,333,745 excludes the treasury shares as stated.
- Note the specific pricing of the buybacks (approx. £10.98 and £10.65) to assess the cost of capital reduction relative to market prices at the time.
- Review the details of the GlaxoSmithKline Employee Trust and SmithKline Beecham Employee Benefit Trust to understand the scope of director interests disclosed.